panaloko gaming

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Former Rockstar Games developer Mike York has chimed in on all the fan theories about GTA 6’s second trailer and what the studio really thinks about the rampant speculation. For over one year , GTA fans have anxiously waited for Rockstar to reveal more information about GTA VI ever since the first trailer made its record-breaking debut . In the time since, fans have poured over every social media post , screenshot, in-game update, and just about anything GTA-related for hints at when the next trailer will be unveiled. Time and time again, these theories have failed to come to fruition – but now, a former dev at Rockstar who worked on GTA 5 and Red Dead Redemption 2 has revealed the truth about these teases. Former GTA dev says Rockstar “trolls” fans with teases In a new YouTube video, York explained that Rockstar is extremely secretive and said that this actually helps them out, because it creates more “allure” towards what is being worked on. “It creates allure and it creates mystery and it creates people talking about [GTA 6] without them having to do anything,” he said. “The more they’re silent, the better it is, because the more people will be antsy and want to talk about it and have this feeling of not knowing what’s going to happen.” According to York , Rockstar is specifically keeping the trailer date vague, because it’s all a marketing tactic that creates wild fan theories. The ex-dev pointed to the GTA Online moon phase theory . Basically, in 2023, the Moon Festival event ended up aligning with the actual moon on December 5, 2023. This was the date that the first GTA 6 trailer released, so players instantly took that as a sign that history could repeat itself. “What’s cool about this stuff is Rockstar can capitalize on it, and if someone has some big theory, even if they didn’t do it on purpose, they can come in and make it look like they did this thing on purpose a long time ago,” he said. “It’s really neat. In a way, this brings the fans together.” Related: York further added how people always dive into these theories and the devs “geek out” about it behind the scenes, noting how a lot of these things are “trolls.” “It’s a mystery to nowhere. It’s just to have you dig and search for stuff and find it, but even though it won’t lead to something, it’ll bring a chase and a journey for players for years to come and it’s really cool.” The dev ended his video by saying he hopes that players will continue to look for signs, because when he used to work for Rockstar, he found it cool to see all the theories people would come up with. It’s not clear if York’s comments will affect the amount of GTA 6 theories on the net, but with the game still slated to release in Fall 2025 , we’ll have to see what the future holds and if any of these conspiracies end up having a shred of truth to them.Bucs RB Bucky Irving gives thanks to O-line for his 185-yard game

Bollywood and Hollywood witnessed an extraordinary year in 2024 with a lineup of films which were a combination of impactful storytelling, star power and technology. From Stree 2 to Inside Out 2, the film industry showcased an impressive lineup of blockbusters that captivated audiences worldwide. (Also Read: HT Rewind 2024 | Only sequels in the building: How Hollywood killed originality as remakes, franchises ruled box office ) Bollywood's Box Office Titans 2024 Kalki 2898 AD Kalki 2898 AD starring Prabhas in the lead role is a sci-fi epic narrating the story of a warrior who tries to earn money illegally in a dystopian future. The star-studded cast includes Prabhas and Bollywood actors Amitabh Bachchan, Deepika Padukone and Disha Patani in the prominent roles. It was directed by Nag Ashwin. With over-the-top graphics and extensive overseas release, the film grossed approx. ₹ 1100 crore at the box office worldwide. Stree 2 This Rajkumar Rao and Shraddha Kapoor starrer was a surprise entry in the club of Bollywood Blockbusters 2024. It minted approx ₹ 850 crore at the worldwide box office. It was directed by Amar Kaushik. The film marked the fourth instalment in the Maddock Supernatural Universe and is the sequel to Stree (2018). Along with the lead cast, the film also stars Pankaj Tripathi, Abhishek Banerjee, and Aparshakti Khurana. Actor Varun Dhawan also had a special cameo in the movie. Bhool Bhulaiyaa 3 The much-anticipated sequel of Kartik Aaryan starrer Bhool Bhulaiyaa 2 didn't disappoint the fans. It was directed by Anees Bazmee and starred Madhuri Dixit, Vidya Balan and Triptii Dimri in the lead roles. The film garnered approx ₹ 422 crore at the box office worldwide. Singham Again Rohit Shetty's Singham Again continued the legacy of his blockbuster "cop universe." Ajay Devgn reprised his iconic role as Bajirao Singham, delivering high-octane action sequences that enthralled fans. This action-packed spectacle raked approx-- ₹ 300 crore globally. Singham Again also stars Kareena Kapoor Khan, Akshay Kumar, Tiger Shroff, Ranveer Singh, and Deepika Padukone among others. Ajay, in a candid conversation with ANI, said, “I am thankful to the audience for giving us so much love. For a long time, the police were always shown in a negative light in films. Singham as well as Gangaajal was one of the first films that showed how an ideal police officer should be. After that, it became a trend of making positive films about police.” Pushpa 2: The Rule It's not even been a month since the film's release, and this Allu Arjun-starrer has already bagged Bollywood's highest-grosser crown. According to Mythri Movie Makers, the official production house of Pushpa 2: The Rule, its worldwide collection has surpassed the ₹ 1700 crore mark. On the massive success of Pushpa 2: The Rule, Allu Arjun expressed his heartfelt gratitude to fans at the "Thank You India" press meet. He said, "I have to say something about the box office number. The number you see is a reflection of the people's love. The numbers are temporary, but the love that is etched in your hearts will remain forever. Thank you for that love." Directed by Sukumar and produced by Mythri Movie Makers and Muttamsetty Media, the film witnessed Allu Arjun, Rashmika Mandanna, and Fahadh Faasil reprising their roles as Pushpa Raj, Srivalli, and Bhanwar Singh Shekawat. Allu Arjun plays the role of the red sandalwood smuggler in the film. Hollywood's Box Office Titans of 2024 As 2024 draws to a close, the global box office has been dominated by sequels and franchise films, engaging audiences worldwide. Take a look at the highest-grossing Hollywood films of the year. Inside Out 2 A sequel that resonated with the viewers and minted nearly USD 1.7 billion at the global box office featured Riley entering puberty and experiencing new, more complex emotions. It was directed by Kelsey Mann and stars Amy Poehler, Maya Hawke and Kensington Tallman in the lead roles. Deadpool & Wolverine The Marvel film never stays out of the race for highest box office grosser. Ryan Reynolds and Hugh Jackman played the roles of Deadpool and Wolverine, respectively. Shawn Levy directed it. It minted over USD 1.138 billion. Despicable Me 4 The love for minion characters in Despicable Me often turns out to be profitable for producers. Directed by Chris Renaud, the main character's voice were given by Steve Carell, Kristen Wiig and Pierre Coffin. It collected around USD 969 million. Dune: Part Two Denis Villeneuve's Dune: Part Two expanded the saga of Paul Atreides while delivering breathtaking visuals and an intense narrative centred around politics, power, and rebellion. The movie grossed over USD 714 million globally. Moana 2 This animated film is another addition to the Hollywood's highest-grossing movies. Directed by David G Derrick, the film revolves around Moana who craves adventure to the far seas of Oceania. It has grossed USD 725 million. As 2024 ends, the box office reports of the highest-grossing films indicate that the audience is inclined towards diverse stories, emotional connections, and stunning visuals. This year's box office hits have set a high standard, and as we look to 2025, the film industry is gearing up for big releases, including Salman Khan's Sikandar, Hrithik Roshan's War 2, Aamir Khan's Sitaare Zameen Par and more.Falcons feeling the pressure at .500 as Cousins' interceptions put spotlight on downturn for offenseInforma TechTarget emerges as a B2B data giantNovember sees high box office turnout as people are returning to cinemas

CMS Energy Corp. stock underperforms Monday when compared to competitorsPaz Moreno was thankful to survive after being bitten by a venomous blue-ringed octopus, but the victim blaming that followed compounded her mental anguish. It's a phenomenon that other animal attack survivors know all too well. Paz Moreno hesitantly takes a step towards the water's edge at Chinaman's Beach. Located in the affluent suburb of Mosman on the shores of Sydney Harbour, there's little to be afraid of — the waves are small and avoidable, the turquoise depths nicely buffered by a comfortable stretch of sandy shore to safely plant your feet. This was once one of Paz's favourite places to swim. When she first moved to Australia from Chile in 2018, Paz quickly and eagerly adapted to Australia's beach lifestyle. "Here, you use the beach as a part of your life every day ... I see people go to the beach in the winter ... there's no problem with that — it's just routine," she says. "In Chile, it's not so common to be in touch with ocean life." Despite this, she developed a reverence for the octopus — pulpo, in Spanish — from a young age. "I felt very ... not scared ... but, 'Oh we have to be careful with these animals', more than sharks or other kinds of creatures, because they are very intelligent," Paz says. For this reason, she "never wanted to have an encounter with an octopus". Paz stands hand-in-hand with her partner Mauricio Quilpatay, their feet buried in the sand, ankle deep. She dreams of going further — back into the water. "I feel it will be soon. A moment in my life that I will return, but I don't think it will be like it used to," Paz says. "The ocean is so huge. It's a fantasy that we are in control." One, two, three pinches In March 2023, just as the summer heat was fading, Paz decided to take a quick dip at Chinaman's Beach with Mauricio, right before she taught her usual Thursday Spanish class. She zipped up her swimsuit, adjusted her snorkel and entered the glittery blue water. "I submerged, and I saw a shell. I picked it up and returned to the surface to look at it," she says. "I checked the shell because the shells can have a crab in it or a snail." It was seemingly empty, so Paz placed the shell in the pocket of her swimsuit, and continued swimming. The first pinch came when she began to leave the water. "It wasn't painful but was kind of annoying." A second pinch. Paz checked her swimsuit and saw nothing. A third pinch. She noticed a lump protruding underneath her swimsuit. She held the lump and unzipped for another check. There was the octopus, "with the full bright blue lines". Paz was aware it was a blue-ringed octopus, as she'd recently watched a TikTok video about the dangerous animal, "so it was pretty fresh". Mauricio quickly leapt into action. "She turned towards me and said take it off. I didn't think about it, I just followed instructions," he says. Mauricio grabbed what he described as a "spherical blob of bright yellow and blue" in his fingertips, flicked it to the sand and dialled triple-0. The couple then managed to contain the octopus in a bottle with some water as they waited for the ambulance. The creature had turned brown with the sun and sand, and Paz was hopeful that, maybe, it wasn't what she thought it was. But when the ambulance arrived, a paramedic flicked the bottle and the octopus once again flashed blue. This was an emergency. Call your family Soon after the ambulance arrived, Paz began to feel a numbness around her mouth and tongue. "Like when you eat spicy food but without the spicy feeling." In the back of the ambulance, she was told to call her family. "I think that was a big red flag for me," Paz says. "I wasn't afraid, I think I had disassociated. I was being very rational about it." In hospital, her respiratory strength, blood pressure and heart rate were decreasing, but overall, she was feeling OK. Being accompanied by the octopus, nicknamed Cuddles by hospital staff, made Paz something of a fascination during her stay. "So many people came to visit and take selfies with the octopus. I think that was the weirdest part." But it isn't surprising. The blue-ringed octopus is one of the many dangerous animals Australians grow up fearing. Thankfully, however, very few of us ever interact with one. When Paz and Mauricio first told their families of their plans to move to Australia, their loved ones were "terrified" for them, over potential encounters with spiders and sharks. Paz reassured them, saying "no worries, I am not going to Queensland" — a place she thought of as home to a disproportionate number of the country's dangerous animals. Paz's apartment is decorated with photos of her travels around the world with Mauricio, and their cat Uli, who continues to be a great comfort to her following the octopus encounter. Finding herself belly to beak with one of Australia's most infamous critters still feels hard to believe, but she says it was what happened after the accident that surprised her the most. In the aftermath, she says two things surprised her: the media's response, and the post-traumatic stress she now experiences, which has prevented her from making a swift return to the ocean, and left her with a disgust for soft, fishy textures. "I was a big fan of ceviche, so when I visited Chile a couple of months ago my family were waiting with a big pot." But Paz couldn't indulge. News of deadly crocodile or shark encounters, Irukandji stings or in this case, blue-ringed octopus bites tend to travel very fast in Australia, even making international headlines. It's not uncommon for bite victims to read articles or conversations online centred around their accident. Paz says she was taken aback by what she saw. "I felt that it was kind of racist," she says, adding that people were commenting on whether the victim was a "foreigner" who didn't respect wildlife. For Mauricio, this couldn't be further from the truth. "Paz is the sort of person who can look at the most hideous animal and find in those eyes a spark," he says. "She sees our cat Uli's eyes in every other animal. It's alien to me and something that I admire about her." Bite Club Dave Pearson understands this phenomenon all too well, which is why he started Beyond the Bite, also known as Bite Club, a place where those who have had traumatic encounters with animals can share their experiences. Dave was bitten by a shark in 2011. Despite the obvious differences between the two encounters, Dave shares a lot of Paz's experiences. "I started looking at the news stories about myself, and that's when I discovered the not-so-social side of social media," he says. "I kind of expected, you know, everyone to go, sorry to hear this happened Dave ... I didn't expect any of the victim blaming." Happy to have escaped from the attack with his life, Dave didn't expect to feel anything other than luck when he left the hospital. Instead, he began waking up screaming. A carefree return to the ocean was also not on the cards. Dave says the stress didn't really hit until six months after he was bitten, when he'd made a physical recovery. He felt lonely in his experience. "Nobody has the answers and that was scary," Dave says. "Mentally you don't know what to expect. "A counsellor came and had a few words to me, and I didn't really understand much of what they were saying or take anything away from it." In 2018, the Bite Club teamed up with the University of Sydney to research the direct and indirect psychological impacts of shark-bite events. The study, a first of its kind, found one third of the members of Bite Club who had been bitten by a shark were experiencing post-traumatic stress disorder. One particular focus of the research was the impact of media exposure on the victims. The group's experiences ultimately led the researchers to advocate for guidelines for the media, akin to those used for reporting on suicide. Once upon a time, human interactions with dangerous animals were not so uncommon. And as these interactions have reduced, interest in them has increased, according to lead researcher Jennifer Taylor, a postdoctoral research associate in the Faculty of Medicine and Health at the University of Sydney. "People spoke a little bit about not only social media, not only traditional media, but every social interaction," Dr Taylor says. "People knew the story, would ask them to retell the story ... and it might have been a space or a place where they actually did not want to get back into retelling their traumatic event. "The other side of it too, and we certainly saw this in the shark space ... in a conservation sense, [is] that these topics can get quite political as well." In Paz's case, people were quick to point out the dangers of picking up shells, which were potential hiding places for the deadly octopus. "Unsympathetic and unsupportive conversations can happen when someone's actually healing from a trauma," Dr Taylor says. "Certainly, these are valuable conversations to have, but perhaps not with someone who's just survived a traumatic event." Dr Taylor acknowledges that the 24-hour news cycle — always hungry for a story — is a challenge, but says journalists must strike a "delicate balance" between "the public's need to know and the person's right to heal in private". Owning the story As Dave sought to recover from the psychological impacts of being bitten by a shark, he found one thing made a big difference: talking to other people in Bite Club who had also had traumatic encounters with dangerous animals, and not just sharks. The group quickly went global with victims of bear, dog, lion and hippo attacks contributing to the conversation. "I just didn't want anyone to feel alone like I did. And it seems to work really well," Dave says. When Dave would meet fellow bite victims, they'd be finishing each other's sentences. In some instances, Dr Taylor says this connection to people with similar experiences and "owning their own story" can be a catalyst for post-traumatic growth. "Once they'd sort of hit that stage or distance or resolved within themselves that it wasn't the worst thing that had ever happened, it was sort of like... If I can help someone going through something similar or help someone ease their discomfort, then I'm prepared to do so." Paz says she was thankful that when news of her octopus bite went around the world, her name was left out of the stories. But now, she has a desire to share what she's learnt. Twisting her earring, which is the shape of an octopus tentacle, Paz says, "If people want me to be the octopus lady, the octopus lady I will be". When Paz describes her experience, she goes between the words "weird" and "random", but her message is clear. No matter how strange the event, if you know you're not feeling like yourself anymore, it's important to seek help. This is something Dr Taylor reinforces. "It's not an aspect of cognition. It's not an intellectual exercise. It's an emotional one," she says. "It's about having felt that depth of fear. Even if you did not lose your life, you thought perhaps you could lose your life, and it is that level of fear that is instrumental ... that is what changes biochemistry, the brain, neurotransmitters, all of that stuff. "So it's really easy to underestimate yourself and the impact of those sorts of events." Determined to return to the water, Paz took "baby steps" to make that happen. And last Sunday, she took her first dip since being bitten. "I'm afraid of this happening again, and I know the probability is very low ... that's an irrational consequence of the accident," Paz says. But allure of the ocean had become irresistible. "I cried immediately after... It was like recovering from something that I lost, but that has always stayed with me. Something deeply mine. "I missed it very much." Credits Related topics Animal Attacks Animals Human Interest Mental Health Port Macquarie Post Traumatic Stress Disorder SydneyATLANTA (AP) — Even the woeful NFC South, where no team has a winning record, can't hide the Atlanta Falcons' offensive shortcomings. Three straight setbacks, including an ugly 17-13 loss to the Los Angeles Chargers, has left the Falcons 6-6 and feeling the pressure. Only a tiebreaker advantage over Tampa Bay has kept the Falcons atop the division. Now the Falcons must prepare to visit streaking Minnesota, which has won five straight . Veteran defensive tackle Grady Jarrett knows the Falcons must solve the flaws which have been exposed in the losing streak. “It’s now or never,” Jarrett said. “You have to flip the mindset fast.” Kirk Cousins threw four interceptions in the loss, matching his career high. Coach Raheem Morris said he didn't consider playing rookie Michael Penix Jr. against the Chargers and won't think about benching Cousins this week. Morris acknowledged the Falcons can't expect to win when turning the ball over four times. It was the latest example of Atlanta's offensive decline. In the three-game losing streak, Cousins has thrown six interceptions with no touchdowns. The Falcons were held under 20 points in each loss. If not for the rash of interceptions which has contributed to the scoring problems, more attention would be devoted to the surge of big plays on defense. The defense forced two fumbles and set a season high with five sacks, including two by Arnold Ebiketie. The Falcons ranked last in the league with only 10 sacks before finding success with their pass rush against Justin Herbert. Herbert was forced to hold the ball while looking for an open receiver, so some credit for the pass-rush success belongs to Atlanta's secondary. The Falcons gave up only two first downs in the second half and 187 yards for the game. Cousins, 36, was expected to be the reliable leader on offense after he signed a four-year, $180 million contract. The four interceptions were his most since 2014 with Washington. Cousins now will be in the spotlight for all the wrong reasons as he returns to Minnesota, his NFL home from 2018-23. Cousins has thrown 13 interceptions, one shy of his career high set in 2022. His passer rating of 90.8 is his lowest since his 86.4 mark as a part-time starter in 2014 with Washington. “Certainly when you haven’t played at the standard you want to a few weeks in a row, you know, you do want to change that, turn it around,” Cousins said. Running back Bijan Robinson had his busiest day of the season, perhaps in an attempt to take heat off Cousins. Robinson's 26 carries set a career high. He ran for 102 yards with a touchdown, his third 100-yard game of the season. He also was heavily involved as a receiver with six catches for 33 yards. With 135 yards from scrimmage, Robinson has eight games this season with more than 100 yards combined as a rusher and receiver, the second-most in the league. Tight end Kyle Pitts had no catches on only two targets. He has only six catches in the last four games after appearing to establish momentum for a big season with two seven-catch games in a span of three weeks in October. Morris noted the Falcons have “so many people that we've got to get the ball to” but noted he'd like to see Pitts more involved. Younghoe Koo's hip issues were such a concern that kicker Riley Patterson was signed to the practice squad on Friday and added to the active roster Saturday. Patterson was on the inactive list as Koo was good on two of three field goals, missing from 35 yards. Koo has made 21 of 29 attempts this season. He did not have more than five misses in any of his first five seasons with Atlanta. 70 — WR Drake London had nine receptions for 86 yards, giving him 70 catches for the season. London, a 2022 first-round draft pick, is the first player in team history with at least 65 receptions in each of his first three seasons. While Ray-Ray McCloud III led the team with a career-best 95 yards on four catches against the Chargers and Darnell Mooney has had some big games, London has been the most consistent receiver. The Falcons face a difficult test Sunday in their visit to Minnesota (10-2), which has five straight wins and is 5-1 at home. AP NFL: https://apnews.com/hub/nflCF Industries Holdings Inc. stock rises Monday, outperforms market

Investigators have asked a South Korean court to issue an arrest warrant for suspended president Yoon Suk Yeol. A joint investigation unit criminally investigating Mr Yoon wants to question him on charges of abuse of authority and orchestrating a rebellion over his short-lived declaration of martial law . While the declaration on 3 December only lasted a few hours, his attempt to ban political activity and censor the media has triggered weeks of political turmoil, halted high-level democracy in South Korea and rattled the country's financial markets. The Corruption Investigation Office, which requested the arrest warrant, is leading the investigation into Mr Yoon and other senior government figures by police and military authorities. Please use Chrome browser for a more accessible video player Mr Yoon has avoided several requests to appear for questioning and also blocked searches of his offices. He has been impeached and would not be immune from criminal prosecution if accused of rebellion or treason. It is not clear whether the court will grant the warrant or whether Mr Yoon can be forced to appear for questioning. More from World Jimmy Carter dies: President Biden leads tributes to 'a man for all time' Former US president Jimmy Carter dies South Korea plane crash latest: Pilot reported bird strike before declaring mayday, says transport ministry Mr Yoon claimed his martial law decree was necessary to overcome political deadlock, despite originally saying it was to "eradicate the despicable pro-North Korean anti-state forces". As well as being accused of attempting to block the parliament vote which overturned martial law, it is claimed he ordered defence counterintelligence officials to detain key opponents. Last week, South Korea's acting president Han Duck-soo was impeached over his refusal to immediately fill three places on the Constitutional Court - which is reviewing Mr Yoon's case. Mr Han was prime minister under Yoon Suk Yeol and has been accused of "acting for insurrection". Mr Han's successor, Choi Sang-mok, has only been acting president since Friday but is dealing with the aftermath of a plane crash which killed 179 people . South Korea's former defence minister Kim Yong Hyun was arrested on 11 December over claims he played a key role in the martial law decree and abused his power. Mr Kim tried to take his own life while being held in detention, officials said. South Korea's national police chief and the top police officer for the capital Seoul have also been detained for their roles in the short-lived decree.

UPDATE -- nCino to Participate in Upcoming Investor Conferences

IBM set to snap seven straight days of gains3 Magnificent Stocks That I’m “Never” Selling

NoneA heartbreaking tribute has been paid to a homeless woman in Co Cork who died following an assault over the weekend. Vanessa O’Callaghan, 36, died in Cork University Hospital on Wednesday (December 4) following an assault outside a soup kitchen in St Patrick’s Street on Sunday (December 1). Gardaí have confirmed that they are investigating Ms O’Callaghan’s death, with tributes pouring in for her following her death — with Roslyn Barrett, a volunteer with Kindness Krew who ran the soup kitchen, saying that she was ‘mannerly and friendly’ prior to her death. Speaking on Cork 96FM’s Opinion Line, Ms Barrett said that she didn’t want Ms O’Callaghan to be ‘another statistic,’ saying ‘It is frightening what is going on and it is very sad that I am on the radio giving my condolences to Vanessa’s family. I hope they get peace. ‘I knew Vanessa very well from our soup run. She was a lovely girl. Never bothered anybody. This unprovoked attack shouldn’t be happening to vulnerable people in the city. ‘There are seven of us on the soup run who risk our lives every Wednesday and Sunday to go in town to feed these vulnerable people. 99% of people appreciate what we give them and are hungry coming up for a second hot dinner.’ ‘That shouldn’t be happening in this day and age. The city council and our Government need to see what is going on in our country. None of our homeless are ever provided with anything by our city council.’ A memorial service for Ms O’Callaghan is expected in the coming days, with Street Angels, who also run homeless services, paying tribute to her on social media. ‘It’s with a very heavy heart that Vanessa has passed away in hospital this afternoon,’ the group wrote on Facebook. ‘RIP my angel, may you get the best bed in heaven heartbroken my friend. Please all say a prayer for her loving soul.’ ‘Gardaí attached to the Serious Crime unit in Anglesea Street, Cork continue to investigate the fatal assault that occurred on St. Patrick’s Street, Cork city on Sunday evening 1st December, 2024,’ a statement from Gardaí said. ‘The woman, aged in her 30s who was found unresponsive and conveyed to Cork University Hospital with serious injuries, has died from her injuries today Wednesday 4th December, 2024. ‘A post mortem examination is due to take place tomorrow, Thursday 5th December, 2024 which is being conducted by the State Pathologist Dr. SallyAnne Collis at Cork University Hospital. ‘Investigating Gardaí continue to appeal to the public for information. ‘Anyone who was in the area of the Savoy, St. Patrick Street, Cork city between 7.15pm and 8.15pm on Sunday evening 1st December, 2024 and who may have information regarding this incident should make contact with the Gardaí.’

Fines for express lane weaving to start with the new yearBarcelona forward Lamine Yamal has won the 2024 Golden Boy award on Wednesday -- the youngest winner of the prize for the best under-21 men's player in the world -- while Barça Femení star Vicky López scooped the Golden Girl award. Yamal, 17, becomes the third Barça player to win the men's award in the last four years, following in the footsteps of teammates Pedri and Gavi . Meanwhile, López won the third edition of the women's award after Jule Brand and Linda Caicedo. Editor's Picks Lewandowski joins exclusive 100 UCL goals club 22h ESPN News Services Messi 'hugely proud' of Flick's Barcelona side 5d Sam Marsden and Moises Llorens Barça to close singing section due to unpaid fines 1d Sam Marsden and Moises Llorens Yamal succeeds Real Madrid 's Jude Bellingham , who won the trophy last year. Other previous winners since the illustrious prize was established by Italian sports newspaper Tuttosport in 2003 include Erling Haaland , Kylian Mbappé and Lionel Messi . It is the latest in a string of accolades Yamal has received since making his debut for Barça's senior side as a 15-year-old in 2023. In October, he won the Kopa Trophy at the Ballon d'Or ceremony, becoming the youngest ever winner of the award which also recognises the best under-21 player in men's football. Yamal also finished eighth in the voting for the Ballon d'Or on the back of a breakout year for club and country, helping Spain win the European Championship last summer and playing a prominent role in a new-look Barça side under Hansi Flick. At the Euros, he was named Young Player of the Tournament, included in the Team of the Tournament and his semifinal goal against France was named the Goal of the Tournament. For Barça, he has broken various age-related records for appearances, goals and assists. In 16 appearances across all competitions this season he has scored six goals and provided eight assists. He has missed Barça's last three games with an ankle injury but coach Flick, speaking after Tuesday's win against Brest in the Champions League, said he could return for Saturday's LaLiga game against Las Palmas .

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; Completed the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company which began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 ; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab; and, Met primary and secondary endpoints in the Phase 3 Pivotal Trial of Mino-Lok ® , demonstrating a statistically significant improvement in time to catheter failure of infected catheters compared to other physician-selected anti-infective lock solutions. Financial Highlights Cash and cash equivalents of $3.3 million as of September 30, 2024 ; R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 ; G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $11.8 million for the full year ended September 30, 2024 , compared to $6.6 million for the full year ended September 30, 2023 ; and, Net loss was $39.4 million , or ($5.97) per share for the full year ended September 30, 2024 compared to a net loss of $32.5 million , or ($5.57) per share for the full year ended September 30, 2023 . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares OutstandingMore than 10 million people empowered so far through the 34 by 34 initiative ATLANTA , Dec. 5, 2024 /PRNewswire/ -- Cox Enterprises today announced that it has empowered 10.6 million people to live more prosperous lives since 2020, a significant milestone in its 34 by 34 social impact initiative . This achievement represents a wide range of efforts across Cox and its businesses, Cox Communications and Cox Automotive. Cox is committed to solving business problems that also remove obstacles present in communities and society at large, from bridging the digital divide to addressing social equity and environmental sustainability challenges. "Cox is a company of innovators, changemakers and believers of being part of something bigger than ourselves," said Maury Wolfe , vice president of Corporate Responsibility and Social Impact at Cox Enterprises. "To drive our 34 by 34 social impact initiative forward, employees across our businesses have led countless acts of volunteering and community engagement, from cleaning up waterways and building outdoor learning labs to mentoring students. We're humbled to see the ripple effect throughout our communities." 34 by 34 focuses on six key pathways to create positive change: technology access, access to lifelong education, employment skills, social equity, environmental sustainability, and good health. These pathways provide a holistic approach to empowering individuals and communities. Key examples of Cox's business and employee volunteering impact include: Lifelong Education: Since 2020 Cox has helped more than 100,000 elementary school students through its work with Junior Achievement Biztowns, where students run a simulated town for a day. Through activities like managing banks, operating restaurants and electing a mayor, students experience firsthand how their lessons apply to real-world scenarios. Social Equity: Through Techstars Powered by Cox Enterprises, startup companies like Branch are helping drive social impact. For example, Branch partnered with local media in Georgia to create a best-in-class voter guide for the 2024 primaries, boosting political engagement. Branch is just one of over 80 startups supported by Techstars Powered by Cox Enterprises, which has positively impacted more than 12,000 additional people through purpose-driven innovations. Environmental Sustainability: Cox is always mindful in its use of natural resources. To date, more than 1.2 million people have benefited from Cox's work to protect and preserve the environment as part of its 34 by 34 initiative. Cox's commitment to environmental sustainability was recently recognized by Keep America Beautiful and the organization's "Do Beautiful Things" Corporate Volunteer Award, which highlights Cox's dedication to volunteerism and environmental sustainability. Visit Cox34by34.com to see stories of our impact and watch this video to learn more about the 34 by 34 initiative. About Cox Enterprises Cox Enterprises is dedicated to empowering people to build a better future for the next generation. Cox is a leader in the broadband, automotive, and media industries, as well as a leading investment platform with strategic positions in emerging technologies driving the future of agriculture, renewable energy, healthtech, and public sector software. Headquartered in Atlanta, Georgia , Cox is a global company with $23 billion in annual revenues and a proud history spanning more than 125 years. To learn more about Cox and its commitment to its people, planet and communities, visit coxenterprises.com . SOURCE Cox Enterprises

Cooperating AI Agents Could Redefine How We Shop and SellFines for express lane weaving to start with the new yearATLANTA (AP) — Even the woeful NFC South, where no team has a winning record, can't hide the Atlanta Falcons' offensive shortcomings. Three straight setbacks, including an ugly 17-13 loss to the Los Angeles Chargers, has left the Falcons 6-6 and feeling the pressure. Only a tiebreaker advantage over Tampa Bay has kept the Falcons atop the division. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Trump asks U.S. Supreme Court to pause law that could ban TikTok

AP Trending SummaryBrief at 9:18 p.m. ESTCEAT Kelani presents traffic management tools to police and SLCMPWhat's the difference between SMD and COB LED Display? 12-02-2024 10:42 PM CET | Associations & Organizations Press release from: ABNewswire In recent years, LED display screens have become an indispensable part of various industries, with technological advancements evolving at an astonishing pace. Among the many innovations, SMD (Surface-Mounted Device) and COB LED display [ https://www.sryled.com/cob-led-display-8k-resolution-for-monitor-room-product/ ] (Chip on Board) technologies stand out for their significant impact. Let's delve into the technical aspects and differences between these two packaging technologies to appreciate their unique advantages and applications. COB Technology: COB (Chip on Board) is a packaging technology where LED chips are directly soldered onto a PCB (Printed Circuit Board). This approach optimizes heat dissipation and ensures a close integration of chips with circuit boards, enhancing performance and durability. Technical Principles COB packaging involves attaching bare LED chips to the PCB using conductive or non-conductive adhesives, followed by wire bonding for electrical connections. To protect the chips and bonding wires from contamination or mechanical damage, they are encapsulated with resin during the final stages of the process. Image: https://ecdn6.globalso.com/upload/p/549/image_product/2024-11/cob-led-display.jpg Key Features * Compact and Integrated Design:By combining the packaging with the PCB, COB minimizes the size of components, optimizes circuit complexity, and enhances system stability. * Superior Durability:The direct chip-to-PCB soldering provides excellent vibration and impact resistance, making COB displays highly reliable even in harsh environments like extreme heat and humidity. * Efficient Heat Dissipation:Thermal conductive adhesives improve heat management, reducing stress on the chips and extending their lifespan. * Cost-Effectiveness in Production:Without the need for pins, COB simplifies the manufacturing process, reduces preparation costs, and supports automation for higher production efficiency. Challenges * Difficult Maintenance:Chips soldered directly onto the PCB are not individually replaceable, necessitating the replacement of the entire PCB in case of failure, increasing maintenance complexity. * Reliability Issues During Production:The adhesive encapsulation can potentially damage delicate components during assembly, affecting production yield. * High Environmental Standards:COB production requires a contamination-free environment, as factors like dust or static electricity can significantly impact product quality. Despite these challenges, COB technology offers cost-effective, high-performance solutions and holds immense potential in smart electronic applications. As advancements in production techniques continue, COB is set to play an increasingly important role. SMD Technology: SMD (Surface-Mounted Device) is another widely adopted packaging technology that directly mounts electronic components onto the surface of a PCB. It is particularly valued in electronics manufacturing for its versatility and efficiency. Main Features * Miniaturized Components:SMD components are compact and lightweight, enabling the design of smaller, lighter, and more portable electronic devices. * Excellent High-Frequency Performance:The short connection paths in SMD designs reduce inductance and resistance, enhancing performance at high frequencies. * Supports Automation:SMD components are compatible with automated assembly processes, improving production efficiency and consistency. * Thermal and Maintenance Benefits:Direct PCB contact improves heat dissipation, while the surface-mounting method facilitates easier repair and replacement of components. Image: https://ecdn6.globalso.com/upload/p/549/image_product/2024-11/smd-led-display.jpg Technological Advancements SMD packaging has evolved into a mainstream technology in electronics, continuously adapting to market demands for higher performance, smaller sizes, and lower costs. COB vs. SMD: Key Differences ASPECT COB LED DISPLAY SMD LED DISPLAY Visual Experience Offers a delicate and uniform surface light source, delivering brighter colors and finer details, ideal for close-up viewing. Relies on point light sources, which may appear less uniform but are suitable for general-purpose displays. Durability Superior protection against external factors due to encapsulation, with excellent waterproof and dustproof capabilities. Easier on-site repair but less robust, as external elements can impact the display more readily. Energy Efficiency Higher efficiency with lower power consumption, thanks to the unobstructed flip-chip process. Slightly higher power consumption compared to COB displays at the same brightness level. Cost and Scalability Theoretical cost benefits, but current production challenges and low yield make it relatively expensive. Lower production costs due to mature manufacturing processes, making it widely used in the market. Maintenance Requires replacement of the entire PCB for repairs, increasing maintenance costs. Individual components are replaceable, simplifying repair and reducing downtime. Image: https://ecdn6.globalso.com/upload/p/549/image_product/2024-11/cob-led-screen-1.jpg Future Trends As the demand for HD LED displays continues to rise, both COB and SMD technologies are finding their niches. Micro LED displays, requiring higher pixel density, increasingly rely on COB's integration capabilities. Meanwhile, SMD remains dominant in applications that prioritize cost efficiency and ease of maintenance. With ongoing advancements in technology and production methods, the gap in cost and yield between COB and SMD is expected to narrow. Together, these technologies are driving the LED display industry toward a future of higher resolution, smarter functionality, and greater energy efficiency. In conclusion, whether you choose COB or SMD depends on the specific application and priorities-be it visual fidelity, durability, cost, or scalability. As these technologies mature, they will continue to complement each other, shaping the future of LED displays in a dynamic and ever-evolving market. Media Contact Company Name: Shenzhen SRYLED Photoelectric Co., Ltd. Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=whats-the-difference-between-smd-and-cob-led-display ] Country: China Website: https://www.sryled.com/ This release was published on openPR.